M3/M21 serum levels in women with adnexal masses and inflammatory diseases

Lukas Hefler, L Hefler, Clemens Tempfer, C Tempfer, Harald Heinzl, H Heinzl, G Haeusler, Guenther Haeusler, P Steindl, Petra Steindl, C Schneeberger, Christian Schneeberger, G Gitsch, C Kainz, Christian Kainz
International journal of cancer · 1998 · vol. 79(4) , pp. 434–438 · doi:10.1002/(sici)1097-0215(19980821)79:4<434::aid-ijc21>3.0.co;2-3 · PMID:9699539 · W1978472618
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

M3/M21 serum levels are not suitable for ovarian cancer screening or differentiating adnexal masses but may serve as a prognostic factor for ovarian cancer survival.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of the present study was to evaluate the clinical usefulness of the cytokeratin tumor marker M3/M21 as a screening marker for ovarian cancer, as a predictive marker in patients with adnexal masses and as a prognostic factor in women with ovarian cancer. To determine the specificity of the M3/M21 test, we investigated M3/M21 serum levels in several benign conditions. This retrospective study comprises 37 patients with ovarian cancer FIGO stages Ia to III. Sera of patients with benign cysts, endometriosis, pelvic inflammatory disease, inflammatory bowel disease and liver cirrhosis were evaluated in 90, 10, 38, 10 and 20 cases, respectively. With a sensitivity of 57% and a specificity of 95%, M3/M21 is not suitable as a screening marker for ovarian cancer. Although M3/M21 is able to discriminate between ovarian cancer and benign adnexal tumors (univariate logistic regression, p = 0.0003), M3/M21 does not provide information additional to CA 125. M3/M21 serum levels are elevated in several benign conditions such as liver cirrhosis and inflammatory bowel disease. In ovarian cancer patients, elevated M3/M21 serum levels prior to therapy were associated with poor overall and disease-free survival (log-rank test, p = 0.03; log-rank test, p = 0.01, respectively). M3/M21, while obviously not suitable for screening or differential diagnosis of adnexal masses, could be useful as an additional prognostic factor in ovarian cancer patients.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Biomarkers, Tumor Keratins Ovarian Neoplasms Pelvic Inflammatory Disease Adenocarcinoma Adenocarcinoma Adult Aged Biomarkers, Tumor Carcinoma Carcinoma Endometriosis Endometriosis Epitopes Evaluation Studies as Topic Female Humans Keratins Middle Aged Ovarian Diseases

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (22)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK